After Indian-made cough syrups were linked to child deaths in Gambia and Uzbekistan, India will only allow cough syrup exports after government laboratory testing, according to a notice on Tuesday (23 May).
Starting from 1 June, in order to be exported, all cough syrups need a certificate of analysis from a government laboratory.
Cough syrups made in India are said to have caused 70 child deaths in Gambia and 19 in Uzbekistan, harming the reputation of India's $41 billion pharmaceutical industry.
India may alter its pharmaceutical industry policy, with plans to enhance cough syrup and raw materials testing, according to a recent Reuters report.
India exported cough syrups worth $17.6 billion in 2022-23, as against $17 billion in 2021-22.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.